NCT02949128 - Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 11, 2017

Primary Completion Date

January 24, 2023

Study Completion Date

January 24, 2023

Conditions

Atypical Hemolytic Uremic Syndrome (aHUS)

Interventions

BIOLOGICAL

Ravulizumab

Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight: ≥ 40 to \< 60 kilograms (kg), 2400 milligrams (mg) loading, then 3000 mg every 8 weeks; ≥ 60 to \< 100 kg, 2700 mg loading, then 3300 mg every 8 weeks; ≥ 100 kg, 3000 mg loading, then 3600 mg every 8 weeks.

Trial Locations (37)

27103

Clinical Trial Site, Winston-Salem

27705

Clinical Trial Site, Durham

43210

Clinical Trial Site, Columbus

46804

Clinical Trial Site, Fort Wayne

46845

Clinical Trial Site, Fort Wayne

Unknown

Clinical Trial Site, Clayton

Clinical Trial Site, Geelong

Clinical Trial Site, Parkville

Clinical Trial Site, Vienna

Clinical Trial Site, Brussels

Clinical Trial Site, London

Clinical Trial Site, Bordeaux

Clinical Trial Site, Clermont-Ferrand

Clinical Trial Site, Lille

Clinical Trial Site, Montpellier

Clinical Trial Site, Nice

Clinical Trial Site, Paris

Clinical Trial Site, Aachen

Clinical Trial Site, Essen

Clinical Trial Site, Hanover

Clinical Trial Site, München

Clinical Trial Site, Tübingen

Clinical Trial Site, Bologna

Clinical Trial Site, Florence

Clinical Trial Site, Saitama

Clinical Trial Site, Tokyo

Clinical Trial Site, Moscow

Clinical Trial Site, Saint Petersburg

Clinical Trial Site, Gyeonggi-do

Clinical Trial Site, Seoul

Clinical Trial Site, Barcelona

Clinical Trial Site, Madrid

Clinical Trial Site, Valencia

Clinical Trial Site, Taichung

Clinical Trial Site, Taipei

Clinical Trial Site, Cardiff

Clinical Trial Site, London